We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
1. Name and Address of Reporting Person * RYAN ARTHUR F | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 8/3/2020 | S(1) | 3 | D | $633.78 (2) | 28640 | D | |||
Common Stock | 8/3/2020 | S(1) | 5 | D | $634.6 (3) | 28635 | D | |||
Common Stock | 8/3/2020 | S(1) | 2 | D | $635.52 (4) | 28633 | D | |||
Common Stock | 8/3/2020 | S(1) | 4 | D | $636.46 (5) | 28629 | D | |||
Common Stock | 8/3/2020 | S(1) | 6 | D | $637.47 (6) | 28623 | D | |||
Common Stock | 8/3/2020 | S(1) | 12 | D | $638.51 (7) | 28611 | D | |||
Common Stock | 8/3/2020 | S(1) | 1 | D | $639.99 | 28610 | D | |||
Common Stock | 8/3/2020 | S(1) | 1 | D | $640.35 | 28609 | D | |||
Common Stock | 8/3/2020 | S(1) | 7 | D | $641.52 (8) | 28602 | D | |||
Common Stock | 8/3/2020 | S(1) | 7 | D | $642.51 (9) | 28595 | D | |||
Common Stock | 8/3/2020 | S(1) | 15 | D | $643.5 (10) | 28580 | D | |||
Common Stock | 8/3/2020 | S(1) | 6 | D | $644.34 (11) | 28574 | D | |||
Common Stock | 8/3/2020 | S(1) | 12 | D | $645.64 (12) | 28562 | D | |||
Common Stock | 8/3/2020 | S(1) | 17 | D | $646.26 (13) | 28545 | D | |||
Common Stock | 8/3/2020 | S(1) | 2 | D | $647.03 (14) | 28543 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
RYAN ARTHUR F 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | X |
Signatures | ||
/s/**Arthur F. Ryan | 8/5/2020 | |
**Signature of Reporting Person | Date |
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions